Clinical trial participant characteristics.

<p>^aContinuous.</p><p>^bFTND/FTCD.</p><p>^cNicotine Replacement Therapy (NRT, NR), Bupropion (BUP, BU), Placebo (PLA, PL), Varenicline (VAR), combined NRT and BUP (NRT+BUP).</p><p>^dEOT ABS = End of treatment seven day point prevalence abstinence, except for trials 00087880 and 00086385 which provided NRT+BUP for 12 weeks and then randomized participants to chronic NRT, chronic BUP or no further treatment.</p><p>^e6MO = Six months.</p><p>Clinical trial participant characteristics.</p

<i>Post-hoc</i> analyses of <i>CYP2A6</i> SNPs and measures of nicotine dependence^a in treatment-seeking smokers.

<p>^aPairwise correlations of cigarettes per day (continuous) with categorical CPD, TTFC and FTND were 0.914, 0.400 and 0.614, of categorical CPD with TTFC and FTND were 0.379 and 0.622, and of TTFC with FTND were 0.799.</p><p>^bAge, age squared, BMI, sex, education, marital status, three principal components of population genetic variation and site. Descriptive and regression analyses were performed on a sample of 2,418 individuals with called genotypes at both rs4803381 and rs1137115.</p><p><i>Post-hoc</i> analyses of <i>CYP2A6</i> SNPs and measures of nicotine dependence<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0126113#t005fn001" target="_blank">^a</a> in treatment-seeking smokers.</p